Chagas Disease (CD), a severe illness caused by the parasite Trypanosoma cruzi, primarily transmitted by triatomine bugs, has turned into a considerable public health concern in Latin America. This disease, named after its discoverer Carlos Ribeiro Justiniano Chagas in 1909, causes heart failure, significant loss of productivity, and results in millions of infections annually.
Leishmaniasis, caused by Leishmania parasites, is another significant tropical disease, mainly affecting impoverished populations in over 90 countries. Cutaneous leishmaniasis affects up to 1.2 million yearly, with most cases in the Americas, Mediterranean, Middle East, and Central Asia. Instances of visceral leishmaniasis, despite observing a downward trend, still affect over 100,000 annually.
Both CD and Leishmaniasis are among the WHO's list of Neglected Tropical Diseases. Control strategies involve treatment, insecticide use, and sanitation improvements, but drug resistance is a growing concern. Current treatments for CD and Leishmaniasis have limitations, including toxicity and resistance.
Discovering new drugs is crucial, and organic synthesis is a valuable method for developing potential candidates, as over 80% of clinical drugs are synthetic. This method allows for creating new compounds with varying structures and properties.
In addition to investigating the anti-parasitic properties of novel natural or synthetic compounds, this Research Topic invites original research articles and review papers that explore a wider range of therapeutic approaches targeting Leishmaniasis and Chagas Disease. These may include:
• Combination therapies, such as targeted treatments with emerging drugs
• Utilization of natural or synthetic compounds as strategic anti-parasitic interventions
• Designing strategies to combat drug resistance.
Keywords:
Chagas Disease, Leishmaniasis, Tropical Diseases, Drug Resistance, Combination Therapies, Anti-parasitic Compounds
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Chagas Disease (CD), a severe illness caused by the parasite Trypanosoma cruzi, primarily transmitted by triatomine bugs, has turned into a considerable public health concern in Latin America. This disease, named after its discoverer Carlos Ribeiro Justiniano Chagas in 1909, causes heart failure, significant loss of productivity, and results in millions of infections annually.
Leishmaniasis, caused by Leishmania parasites, is another significant tropical disease, mainly affecting impoverished populations in over 90 countries. Cutaneous leishmaniasis affects up to 1.2 million yearly, with most cases in the Americas, Mediterranean, Middle East, and Central Asia. Instances of visceral leishmaniasis, despite observing a downward trend, still affect over 100,000 annually.
Both CD and Leishmaniasis are among the WHO's list of Neglected Tropical Diseases. Control strategies involve treatment, insecticide use, and sanitation improvements, but drug resistance is a growing concern. Current treatments for CD and Leishmaniasis have limitations, including toxicity and resistance.
Discovering new drugs is crucial, and organic synthesis is a valuable method for developing potential candidates, as over 80% of clinical drugs are synthetic. This method allows for creating new compounds with varying structures and properties.
In addition to investigating the anti-parasitic properties of novel natural or synthetic compounds, this Research Topic invites original research articles and review papers that explore a wider range of therapeutic approaches targeting Leishmaniasis and Chagas Disease. These may include:
• Combination therapies, such as targeted treatments with emerging drugs
• Utilization of natural or synthetic compounds as strategic anti-parasitic interventions
• Designing strategies to combat drug resistance.
Keywords:
Chagas Disease, Leishmaniasis, Tropical Diseases, Drug Resistance, Combination Therapies, Anti-parasitic Compounds
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.